Hirokazu Tanaka

8PUBLICATIONS
8CO-AUTHORS
Haematological tumoursImmunogenetics (incl. genetic immunology)Molecular targetsMedical mycologyHaematology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jun 12, 2026
The Prognostic Value of Circulating Tumor DNA for Clinical Outcomes in Patients Undergoing Hematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis.

|Feb 02, 2026
Clonal Complexity Defines Distinct Tumor-Intrinsic Biology and Prognosis in Diffuse Large B-Cell Lymphoma.

Takahiro Haeno, Kazuko Sakai, Shuji Minamoto

|Oct 28, 2025
Antipsychotic Chlorpromazine Suppresses STAT5 Signaling, Overcomes Resistance Mediated by the Gatekeeper Mutation FLT3-ITD/F691L, and Synergizes with Quizartinib in FLT3-ITD-Positive Cells.

Aki Fujii-Hanamoto, Hirokazu Tanaka, Ko Fujimoto

|Feb 08, 2022
CD34+ myeloma cells with self-renewal activities are therapy-resistant and persist as MRD in cell cycle quiescence.

Kentaro Serizawa, Hirokazu Tanaka, Takeshi Ueda

|Feb 02, 2022
C-type lectin-like receptor 2 specifies a functionally distinct subpopulation within phenotypically defined hematopoietic stem cell population that contribute to emergent megakaryopoiesis.

Takahiro Kumode, Hirokazu Tanaka, Jorge Luis Esipinoza

|Aug 20, 2020
Chlorpromazine eliminates acute myeloid leukemia cells by perturbing subcellular localization of FLT3-ITD and KIT-D816V.

Shinya Rai, Hirokazu Tanaka, Mai Suzuki

Pageof 2

Frequent Collaborators

5 joint publications

Shinya Rai

4 joint publications

Jorge Luis Espinoza

2 joint publications

Itaru Matsumura

2 joint publications

Takahiro Haeno